NCT06387368View on ClinicalTrials.gov

Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

488

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

March 31, 2028

Study Completion Date

August 31, 2028

Conditions
Pancreatic Cancer Non-resectable
Interventions
DRUG

Huaier Granule

Huaier Granules: Oral administration, 10g once, 3 times a day. Capecitabine: oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d), day 1-14, once every 3 weeks.

DRUG

Capecitabine

Oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d), day 1-14, once every 3 weeks.

All Listed Sponsors
collaborator

LinkDoc Technology (Beijing) Co. Ltd.

INDUSTRY

collaborator

Huazhong University of Science and Technology

OTHER

lead

Xi'an Jiaotong University

OTHER

NCT06387368 - Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter